Is ROOT Stock the Next Big Thing?
Root Holdings (NASDAQ:ROOT) is the parent company of Root Insurance,…
Sell
32
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$110.05
Seasonality move
:
17.35%
Day range:
$109.76 - $117.12
52-week range:
$99.06 - $148.06
Dividend yield:
0%
P/E ratio:
12.52x
P/S ratio:
1.74x
P/B ratio:
1.63x
Volume:
2.2M
Avg. volume:
1.3M
1-year change:
-4.49%
Market cap:
$6.7B
Revenue:
$4.1B
EPS (TTM):
$8.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$1.1B | $5.78 | 9.16% | 309.21% | $193.44 |
|
ALKS
Alkermes PLC
|
$346.8M | $0.47 | -13.12% | -11.05% | $39.20 |
|
AMRN
Amarin Corp PLC
|
$48.1M | -$0.03 | -11.04% | -- | $1.00 |
|
CMRX
Chimerix
|
-- | -$0.30 | 7665% | -8% | $8.54 |
|
MDT
Medtronic PLC
|
$8.8B | $1.58 | 2.59% | 221.68% | $97.09 |
|
PRGO
Perrigo Co PLC
|
$1.1B | $0.64 | 0.89% | 5337.6% | $34.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$110.04 | $193.44 | $6.7B | 12.52x | $0.00 | 0% | 1.74x |
|
ALKS
Alkermes PLC
|
$30.04 | $39.20 | $4.9B | 13.84x | $0.00 | 0% | 3.27x |
|
AMRN
Amarin Corp PLC
|
$0.40 | $1.00 | $167.2M | -- | $0.00 | 0% | 0.73x |
|
CMRX
Chimerix
|
$8.53 | $8.54 | $800.1M | -- | $0.00 | 0% | -- |
|
MDT
Medtronic PLC
|
$82.88 | $97.09 | $106.3B | 25.19x | $0.70 | 3.38% | 3.24x |
|
PRGO
Perrigo Co PLC
|
$26.31 | $34.60 | $3.6B | -- | $0.29 | 4.25% | 0.83x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
59.88% | 0.953 | 81.81% | 3.57x |
|
ALKS
Alkermes PLC
|
-- | 1.084 | -- | 2.45x |
|
AMRN
Amarin Corp PLC
|
-- | 0.049 | -- | 2.31x |
|
CMRX
Chimerix
|
-- | -9.573 | -- | 5.55x |
|
MDT
Medtronic PLC
|
34.97% | 0.718 | 22.74% | 1.19x |
|
PRGO
Perrigo Co PLC
|
45.58% | -0.127 | 103.15% | 1.15x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$959.5M | $190.8M | 5.74% | 14.39% | 16.95% | $385.3M |
|
ALKS
Alkermes PLC
|
$367.9M | $162.7M | 23.97% | 28.24% | 40.59% | $180.6M |
|
AMRN
Amarin Corp PLC
|
-$9.6M | -$52.5M | -15.41% | -15.41% | -60.86% | -$13.3M |
|
CMRX
Chimerix
|
-- | -$24.6M | -56.64% | -56.65% | -43073.68% | -$19.4M |
|
MDT
Medtronic PLC
|
$5.5B | $1.7B | 5.58% | 8.56% | 20.73% | $2.1B |
|
PRGO
Perrigo Co PLC
|
$385.9M | $164.8M | -1.98% | -3.76% | 9.94% | $274.9M |
Jazz Pharmaceuticals PLC vs. Competitors
-
Which has Higher Returns JAZZ or ALKS?
Alkermes PLC has a net margin of 17.56% compared to Jazz Pharmaceuticals PLC's net margin of 34.07%. Jazz Pharmaceuticals PLC's return on equity of 14.39% beat Alkermes PLC's return on equity of 28.24%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.17% $3.11 $10.2B ALKSAlkermes PLC85.55% $0.88 $1.5B -
What do Analysts Say About JAZZ or ALKS?
Jazz Pharmaceuticals PLC has a consensus price target of $193.44, signalling upside risk potential of 75.8%. On the other hand Alkermes PLC has an analysts' consensus of $39.20 which suggests that it could grow by 30.49%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC9 2 0 ALKSAlkermes PLC8 6 0 -
Is JAZZ or ALKS More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.419, which suggesting that the stock is 58.096% less volatile than S&P 500. In comparison Alkermes PLC has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.101%.
-
Which is a Better Dividend Stock JAZZ or ALKS?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Alkermes PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ALKS?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are larger than Alkermes PLC quarterly revenues of $430M. Jazz Pharmaceuticals PLC's net income of $191.1M is higher than Alkermes PLC's net income of $146.5M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 12.52x while Alkermes PLC's PE ratio is 13.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.74x versus 3.27x for Alkermes PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.74x 12.52x $1.1B $191.1M ALKSAlkermes PLC3.27x 13.84x $430M $146.5M
-
Which has Higher Returns JAZZ or AMRN?
Amarin Corp PLC has a net margin of 17.56% compared to Jazz Pharmaceuticals PLC's net margin of -78.03%. Jazz Pharmaceuticals PLC's return on equity of 14.39% beat Amarin Corp PLC's return on equity of -15.41%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.17% $3.11 $10.2B AMRNAmarin Corp PLC-15.36% -$0.12 $486.2M -
What do Analysts Say About JAZZ or AMRN?
Jazz Pharmaceuticals PLC has a consensus price target of $193.44, signalling upside risk potential of 75.8%. On the other hand Amarin Corp PLC has an analysts' consensus of $1.00 which suggests that it could grow by 147.77%. Given that Amarin Corp PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe Amarin Corp PLC is more attractive than Jazz Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC9 2 0 AMRNAmarin Corp PLC0 1 0 -
Is JAZZ or AMRN More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.419, which suggesting that the stock is 58.096% less volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 1.384, suggesting its more volatile than the S&P 500 by 38.378%.
-
Which is a Better Dividend Stock JAZZ or AMRN?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or AMRN?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are larger than Amarin Corp PLC quarterly revenues of $62.3M. Jazz Pharmaceuticals PLC's net income of $191.1M is higher than Amarin Corp PLC's net income of -$48.6M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 12.52x while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.74x versus 0.73x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.74x 12.52x $1.1B $191.1M AMRNAmarin Corp PLC0.73x -- $62.3M -$48.6M
-
Which has Higher Returns JAZZ or CMRX?
Chimerix has a net margin of 17.56% compared to Jazz Pharmaceuticals PLC's net margin of -40270.18%. Jazz Pharmaceuticals PLC's return on equity of 14.39% beat Chimerix's return on equity of -56.65%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.17% $3.11 $10.2B CMRXChimerix-- -$0.25 $121.7M -
What do Analysts Say About JAZZ or CMRX?
Jazz Pharmaceuticals PLC has a consensus price target of $193.44, signalling upside risk potential of 75.8%. On the other hand Chimerix has an analysts' consensus of $8.54 which suggests that it could grow by 0.12%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Chimerix, analysts believe Jazz Pharmaceuticals PLC is more attractive than Chimerix.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC9 2 0 CMRXChimerix1 3 0 -
Is JAZZ or CMRX More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.419, which suggesting that the stock is 58.096% less volatile than S&P 500. In comparison Chimerix has a beta of -0.176, suggesting its less volatile than the S&P 500 by 117.551%.
-
Which is a Better Dividend Stock JAZZ or CMRX?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or CMRX?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are larger than Chimerix quarterly revenues of $57K. Jazz Pharmaceuticals PLC's net income of $191.1M is higher than Chimerix's net income of -$23M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 12.52x while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.74x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.74x 12.52x $1.1B $191.1M CMRXChimerix-- -- $57K -$23M
-
Which has Higher Returns JAZZ or MDT?
Medtronic PLC has a net margin of 17.56% compared to Jazz Pharmaceuticals PLC's net margin of 15.61%. Jazz Pharmaceuticals PLC's return on equity of 14.39% beat Medtronic PLC's return on equity of 8.56%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.17% $3.11 $10.2B MDTMedtronic PLC66.49% $1.01 $76.2B -
What do Analysts Say About JAZZ or MDT?
Jazz Pharmaceuticals PLC has a consensus price target of $193.44, signalling upside risk potential of 75.8%. On the other hand Medtronic PLC has an analysts' consensus of $97.09 which suggests that it could grow by 17.15%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Medtronic PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC9 2 0 MDTMedtronic PLC11 14 1 -
Is JAZZ or MDT More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.419, which suggesting that the stock is 58.096% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.554%.
-
Which is a Better Dividend Stock JAZZ or MDT?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.38% to investors and pays a quarterly dividend of $0.70 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or MDT?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are smaller than Medtronic PLC quarterly revenues of $8.3B. Jazz Pharmaceuticals PLC's net income of $191.1M is lower than Medtronic PLC's net income of $1.3B. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 12.52x while Medtronic PLC's PE ratio is 25.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.74x versus 3.24x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.74x 12.52x $1.1B $191.1M MDTMedtronic PLC3.24x 25.19x $8.3B $1.3B
-
Which has Higher Returns JAZZ or PRGO?
Perrigo Co PLC has a net margin of 17.56% compared to Jazz Pharmaceuticals PLC's net margin of -3.91%. Jazz Pharmaceuticals PLC's return on equity of 14.39% beat Perrigo Co PLC's return on equity of -3.76%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.17% $3.11 $10.2B PRGOPerrigo Co PLC33.9% -$0.32 $7.9B -
What do Analysts Say About JAZZ or PRGO?
Jazz Pharmaceuticals PLC has a consensus price target of $193.44, signalling upside risk potential of 75.8%. On the other hand Perrigo Co PLC has an analysts' consensus of $34.60 which suggests that it could grow by 31.51%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Perrigo Co PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC9 2 0 PRGOPerrigo Co PLC1 3 0 -
Is JAZZ or PRGO More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.419, which suggesting that the stock is 58.096% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.326%.
-
Which is a Better Dividend Stock JAZZ or PRGO?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.25% to investors and pays a quarterly dividend of $0.29 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or PRGO?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Jazz Pharmaceuticals PLC's net income of $191.1M is higher than Perrigo Co PLC's net income of -$44.5M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 12.52x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.74x versus 0.83x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.74x 12.52x $1.1B $191.1M PRGOPerrigo Co PLC0.83x -- $1.1B -$44.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta a Good Stock to Buy?
Okta (NASDAQ:OKTA) is used by some of the largest firms…
Is Fidelity High Dividend ETF a Good Investment Now?
Fidelity’s High Dividend ETF (FDVV) is a fund that offers…
Stock Ideas
Sell
37
Is AAPL Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
37
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
31
Is NVDA Stock a Buy?
Market Cap: $2.3T
P/E Ratio: 32x
Alerts
Sell
45
RGC alert for Apr 5
Regencell Bioscience Holdings [RGC] is up 32.59% over the past day.
Sell
25
GDXU alert for Apr 5
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 27.33% over the past day.
Buy
76
SOXS alert for Apr 5
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 23.96% over the past day.
